{
    "clinical_study": {
        "@rank": "73895", 
        "arm_group": {
            "arm_group_label": "Bevacizumab Plus Chemotherapy"
        }, 
        "brief_summary": {
            "textblock": "To assess the safety profile of bevacizumab in combination with chemotherapy for the\n      treatment of metastatic colorectal cancer"
        }, 
        "brief_title": "Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer", 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a multi-centre, observational, non-interventional study. Patients with metastatic\n      colorectal cancer eligible for Bevacizumab in combination with chemotherapy treatment will\n      be enrolled in this trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  with histologically confirmed metastatic colorectal cancer\n\n          -  patients with metastatic colorectal cancer who are eligible for Bevacizumab in\n             combination with chemotherapy treatment\n\n          -  Written informed consent\n\n          -  Unlimited line of treatment (first-line or second line is not limited)\n\n        Exclusion Criteria:\n\n        Patients who are not eligible for Bevacizumab treatment according to locally approved\n        Bevacizumab China package insert will be excluded. The following patients are not eligible\n        for Bevacizumab treatment according to local Bevacizumab China package insert:\n\n          -  Recent history of serious hemorrhage or hemoptysis of \u22651/2 teaspoon of red blood\n\n          -  Proteinuria at baseline: Patients discovered to have \u2265 2 grams of proteinuria/24\n             hours *\n\n               -  The measurement of 24-hour proteinuria level is recommended for patients with\n                  moderate to high proteinuria risk indicated by clinical judgement. The treatment\n                  with bevacizumab should be delayed when proteinuria is \u22652g/24 hours.\n\n          -  Major surgical procedure within 28 days prior to treatment initiation, or not fully\n             healed wounds\n\n          -  Pregnant or lactating women\n\n          -  Excluding patients known to be allergic to bevacizumab or any of the excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with histologically confirmed metastatic colorectal cancer are eligible"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912443", 
            "org_study_id": "ML28629"
        }, 
        "intervention": {
            "arm_group_label": "Bevacizumab Plus Chemotherapy", 
            "description": "5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.", 
            "intervention_name": "bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "Avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Sun Yat-Sen University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ruihua Xu, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "13939039058@126.com", 
                    "last_name": "Qingxia Fan, Doctor"
                }, 
                "contact_backup": {
                    "email": "hewei726@126.com", 
                    "last_name": "Wei He, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "state": "Henan", 
                        "zip": "450052"
                    }, 
                    "name": "The First Affiliated Hospital of Zhengzhou University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nkyang@126.com", 
                    "last_name": "Jianjun Yang, Doctor"
                }, 
                "contact_backup": {
                    "email": "yaoshunan07@126.com", 
                    "last_name": "Shuna Yao, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "state": "Henan", 
                        "zip": "450008"
                    }, 
                    "name": "Henan Cancer Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "poryqin@aliyun.com", 
                    "last_name": "Baoli Qin, Doctor"
                }, 
                "contact_backup": {
                    "email": "wangzhongmiao@126.com", 
                    "last_name": "Zhongmiao Wang, Master"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110042"
                    }, 
                    "name": "Liaoning Cancer Hosptial & Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Yanjin-1111@163.com", 
                    "last_name": "Jin Yan, Bachelor degree"
                }, 
                "contact_backup": {
                    "email": "zheng-ych@sohu.com", 
                    "last_name": "Yangchun Zheng, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "The Second People's Hospital of Sichuan"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "daigh60@sohu.com", 
                    "last_name": "Guanghai Dai, Master"
                }, 
                "contact_backup": {
                    "email": "michaelia814105@hotmail.com", 
                    "last_name": "Hui Mao, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100853"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dunan304@163.com", 
                    "last_name": "Nan Du, Doctor"
                }, 
                "contact_backup": {
                    "email": "18810494306@126.com", 
                    "last_name": "Nan Qi, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100048"
                    }, 
                    "name": "First Affiliated Hospital of PLA General Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "xurh@sysucc.org.cn", 
            "last_name": "Ruihua Xu, Professor", 
            "phone": "+86-20-87343804"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Gastrointestinal perforation, thromboembolic event, wound healing complication, bleeding, hypertension and proteinuria", 
                "measure": "Incidence, nature and severity of adverse events of special interest", 
                "safety_issue": "Yes", 
                "time_frame": "Four years"
            }, 
            {
                "measure": "Incidence, nature and severity of bevacizumab related serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Four years"
            }, 
            {
                "measure": "Onset time of adverse event associated with bevacizumab", 
                "safety_issue": "Yes", 
                "time_frame": "Four years"
            }, 
            {
                "description": "Complete blood cell count, electrolytes, hepatic and renal function, coagulation parameters, urinalysis or urine protein", 
                "measure": "Laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Four years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912443"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Ruihua Xu", 
            "investigator_title": "vice president of SunYat-sen University Cancer Center,head of medical oncology department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from the diagnosis of colorectal cancer to death due to various causes. Patients who do not die at the end of study will be truncated when they do not die at the last collection.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Four years"
            }, 
            {
                "description": "The best overall response status determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria is defined as the best response status recorded from the enrollment to disease progression (the minimal measurement from baseline assessment is used as the reference for progression). ORR includes complete response (CR) and partial response (PR). The value of change will be summarized according to different treatment lines.", 
                "measure": "Overall response rate (ORR) of treatment line", 
                "safety_issue": "No", 
                "time_frame": "Four years"
            }, 
            {
                "description": "Time from the enrollment to disease progression or death due to various causes, whichever is earlier (Disease progression is according to RECIST 1.1 criteria for tumor assessment). Patients who do not have disease progression or death at the end of study will be truncated at the last tumor assessment. The value of change will be summarized according to different treatment lines.", 
                "measure": "Progression-free survival (PFS) of treatment line:", 
                "safety_issue": "No", 
                "time_frame": "Four years"
            }, 
            {
                "description": "The proportion of patients without disease progression within one year since enrollment or with death for other reasons based on analytical population. The value of change will be summarized according to different treatment lines.", 
                "measure": "One-year disease-free progression rate of treatment line", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "The proportion of patients without death within one year since enrollment based on analytical population. The value of change will be summarized according to different treatment lines.", 
                "measure": "One-year survival rate of treatment line", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "Time from the enrollment to death due to various causes. Patients who do not die at the end of study will be truncated when they do not die at the last collection.", 
                "measure": "Overall survival (OS) of treatment line", 
                "safety_issue": "No", 
                "time_frame": "Four years"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": {
                "agency": "PROSWELL MEDICAL COMPANY ,China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}